Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-blind, Placebo-controlled, Single Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY 3018250 in Chinese Healthy Participants

NCT06619483 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06619483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06619483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-blind, Placebo-controlled, Single Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY 3018250 in Chinese Healthy Participants
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
October 10, 2024
Completion date
January 24, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute venous and arterial thrombotic and thromboembolic events, healthy volunteers